The Benefits of Continued Use of Ovarian Function Suppression After 5 Years

Condition(s) studied

Investigational drug(s) / intervention(s)

OFS continues to use group after 5 years use: Patients included in the group continued or discontinued to use goserelin or leuprolide after 5 years use.

Immunohistochemical detection of HR status: Enrolled patients must be HR-positive premenopausal breast cancer patients

Study summary

To observe and evaluate the clinical efficacy and safety of continuous use of OFS for premenopausal patients with early breast cancer after 5 years use of OFS.

This study is a multicenter, prospective, observational, non randomized controlled, open-label real world study based on hospital medical record system data, aimed at evaluating the benefits of continuing to use OFS after 5 years of use. The retrospective analysis plan includes patient data from September 1, 2023 to September 1, 2026. Join two cohorts: the continued use group and the discontinued use group after 5 years of OFS, respectively.

Eligibility

Primary outcome measure(s)

• invasive disease-free survival — 5 years
  The main effect evaluation index was invasive disease-free survival (iDFS)

Trial sites (1)

Other trials for the same condition